Free Trial

This company has been marked as potentially delisted and may not be actively trading.

FS Development (FSDC) Competitors

FS Development logo

FSDC vs. MOR, GMTX, CALT, ZYME, MENS, SBTX, MBX, AVTE, NLTX, and CYBN

Should you be buying FS Development stock or one of its competitors? The main competitors of FS Development include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), and Cybin (CYBN).

FS Development vs. Its Competitors

FS Development (NASDAQ:FSDC) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

FS Development has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. FS Development's return on equity of 0.00% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
FS DevelopmentN/A N/A N/A
MorphoSys -226.79%-694.31%-22.55%

FS Development has higher earnings, but lower revenue than MorphoSys.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FS DevelopmentN/AN/AN/AN/AN/A
MorphoSys$238.28M11.99-$205.35M-$3.48-5.45

In the previous week, FS Development's average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score.

Company Overall Sentiment
FS Development Neutral
MorphoSys Neutral

89.8% of FS Development shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

FS Development beats MorphoSys on 4 of the 6 factors compared between the two stocks.

Get FS Development News Delivered to You Automatically

Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FSDC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FSDC vs. The Competition

MetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$744.45M$774.28M$5.74B$9.53B
Dividend YieldN/A4.84%4.70%4.05%
P/E RatioN/A1.3928.2520.08
Price / SalesN/A24.87432.1087.56
Price / CashN/A19.5625.1828.40
Price / BookN/A6.828.435.80
Net IncomeN/A-$4.22M$3.25B$259.24M

FS Development Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FSDC
FS Development
N/A$59.48
-1.9%
N/A+32.7%$744.45MN/A0.00N/A
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
GMTX
Gemini Therapeutics
N/A$60.74
+2.3%
N/A+32.7%$2.63BN/A-60.7430
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
ZYME
Zymeworks
2.4834 of 5 stars
$14.29
-0.2%
$21.00
+47.0%
+25.2%$995.77M$93.38M-9.53460News Coverage
Upcoming Earnings
MENS
Jyong Biotech
N/A$11.15
+10.8%
N/AN/A$764.84MN/A0.0031Quiet Period Expiration
SBTX
Silverback Therapeutics
N/A$17.59
-1.5%
N/A+62.8%$634.26MN/A-7.2783High Trading Volume
MBX
MBX Biosciences
2.2414 of 5 stars
$13.68
+16.9%
$37.57
+174.6%
N/A$457.24MN/A0.0036High Trading Volume
AVTE
Aerovate Therapeutics
N/A$8.98
+3.3%
N/A-88.2%$260.29MN/A-3.0020High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$22.34
-1.2%
N/A-49.3%$209.95MN/A-7.1890High Trading Volume
CYBN
Cybin
2.8126 of 5 stars
$7.76
+0.4%
$85.00
+995.4%
N/A$178.67MN/A-1.7750

Related Companies and Tools


This page (NASDAQ:FSDC) was last updated on 7/29/2025 by MarketBeat.com Staff
From Our Partners